Federal Judge Halts Colorado's Novel Drug Price Cap on Amgen's Enbrel

A federal judge has temporarily blocked Colorado's groundbreaking effort to cap the price of certain prescription drugs, specifically preventing a state panel from setting a price ceiling on Amgen's Enbrel. This decision represents a setback for Colorado's innovative approach to controlling drug costs, which aimed to make expensive treatments more affordable for residents. The state's initiative sought to establish an upper limit on high-cost medications. The judicial intervention questions state-level regulatory power over drug pricing, highlighting the complex legal landscape and ongoing tension between state governments' efforts to reduce healthcare costs and the pharmaceutical industry.